Switch theme
Sign up to access all valuation multiples
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
2013
97
LTM Revenue $75.0M
Last FY EBITDA -$38.5M
$375M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Theravance has a last 12-month revenue (LTM) of $75.0M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Theravance achieved revenue of $64.4M and an EBITDA of -$38.5M.
Theravance expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Theravance valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $75.0M | XXX | $64.4M | XXX | XXX | XXX |
| Gross Profit | $75.0M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$38.5M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -60% | XXX | XXX | XXX |
| EBIT | -$21.3M | XXX | -$42.4M | XXX | XXX | XXX |
| EBIT Margin | -28% | XXX | -66% | XXX | XXX | XXX |
| Net Profit | -$42.4M | XXX | -$56.4M | XXX | XXX | XXX |
| Net Margin | -56% | XXX | -88% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Theravance's stock price is $9.
Theravance has current market cap of $458M, and EV of $375M.
See Theravance trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $375M | $458M | XXX | XXX | XXX | XXX | $-0.86 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Theravance has market cap of $458M and EV of $375M.
Theravance's trades at 5.8x EV/Revenue multiple, and -9.8x EV/EBITDA.
Equity research analysts estimate Theravance's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Theravance has a P/E ratio of -10.8x.
See valuation multiples for Theravance and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $458M | XXX | $458M | XXX | XXX | XXX |
| EV (current) | $375M | XXX | $375M | XXX | XXX | XXX |
| EV/Revenue | 5.0x | XXX | 5.8x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -9.8x | XXX | XXX | XXX |
| EV/EBIT | -17.6x | XXX | -8.8x | XXX | XXX | XXX |
| EV/Gross Profit | 5.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | -10.8x | XXX | -8.1x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -31.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialTheravance's last 12 month revenue growth is 14%
Theravance's revenue per employee in the last FY averaged $0.7M, while opex per employee averaged $1.1M for the same period.
Theravance's rule of 40 is -60% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Theravance's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Theravance and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 14% | XXX | 11% | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -60% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -60% | XXX | -45% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.7M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 58% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 166% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Theravance acquired XXX companies to date.
Last acquisition by Theravance was XXXXXXXX, XXXXX XXXXX XXXXXX . Theravance acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Theravance founded? | Theravance was founded in 2013. |
| Where is Theravance headquartered? | Theravance is headquartered in United States of America. |
| How many employees does Theravance have? | As of today, Theravance has 97 employees. |
| Who is the CEO of Theravance? | Theravance's CEO is Mr. Rick E. Winningham. |
| Is Theravance publicy listed? | Yes, Theravance is a public company listed on NAS. |
| What is the stock symbol of Theravance? | Theravance trades under TBPH ticker. |
| When did Theravance go public? | Theravance went public in 2014. |
| Who are competitors of Theravance? | Similar companies to Theravance include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Theravance? | Theravance's current market cap is $458M |
| What is the current revenue of Theravance? | Theravance's last 12 months revenue is $75.0M. |
| What is the current revenue growth of Theravance? | Theravance revenue growth (NTM/LTM) is 14%. |
| What is the current EV/Revenue multiple of Theravance? | Current revenue multiple of Theravance is 5.0x. |
| Is Theravance profitable? | Yes, Theravance is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
